While the salaries themselves have only been a small part of the overall loss, the amount of the salaries is a problem to almost all investors, even positive ones. Yes, revenue growth has been extraordinary but losses continue to mount up. On top of that, we get virtually no communication from muscle pharm with PRs or through investor relations. Many of us here fail to see how muscle pharm execs have positioned themselves for institutional investors when the same principles that led us to the toxic financing are still in place, at least as far as we know.
As a new investor, maybe you can lend some objective insight into the following questions:
1) What are they doing to improve their bottom line? The filings are very generic and could be anything from cutting the purchase of pens to putting pressure on their manufacturer.
2) In a PR last year, they told us their goal was to be CFP by Q1 2012, what happened to that goal? (I know you're focused on the future, but this question about the past, relates to plans going forward).
3) If the reason for not meeting that goal was to push for rapid expansion internationally, what is the end goal of the rapid expansion? Ie, at what point will the company focus on bottom line instead of revenues.
I really doubt institutional investors will look at this and say now there's a good gamble without questions like these being addressed. Institutional investors will not only look at the revenues because nothing has changed from when the revenues were growing exponentially till present so in their eyes, this will mean more dilution to fund the growth, which muscle pharm cannot do without taking a loss it seems.
